SLC44A4 and prostate carcinoma: Thus, ADCs directed against SLC44A4 could potentially be evaluated in breast cancer; CD71, PTK7 and SLC44A4 in colorectal cancer; SLC44A4 in lung cancer; LIV‐1 in prostate cancer, and finally CD71 and CD74 in gastric cancer.